Buprenorphine and Lomitapide: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Lomitapide
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Lomitapide can slow down the liver enzyme (called CYP3A4) that normally breaks down your buprenorphine. When that enzyme is slowed, more buprenorphine stays in your body. That can make its effects stronger and last longer, including too much sleepiness or slowed, shallow breathing.
The good news is this is very manageable. Your care team can tailor your buprenorphine dose and keep a closer eye on you. Please don't start, stop, or change either medicine on your own. Just let your pharmacist or doctor know you take both so they can watch for any signs of over-sedation and keep you safe.
Mechanism: Lomitapide inhibits CYP3A4, the primary enzyme metabolizing buprenorphine. Buprenorphine is an active drug (not a prodrug requiring CYP3A4 activation), so reduced clearance increases its plasma exposure.
Effect / direction: Increased buprenorphine AUC and Cmax, with prolonged opioid effects including sedation and respiratory depression.
Evidence: Probable; severity major; onset unspecified.
- If starting lomitapide, consider reducing buprenorphine dose until stable; monitor for sedation and respiratory depression.
- On lomitapide discontinuation, consider dose increase and monitor for withdrawal.
- For subQ/long-acting forms, monitor for over-medication; transition to a titratable formulation if precise adjustment is needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
When buprenorphine is taken together with a CYP3A4 inhibitor, plasma levels of buprenorphine can rise, potentially leading to extended opioid effects such as respiratory depression. In a buprenorphine-treated patient who requires a CYP3A4 inhibitor, it is advisable to lower the buprenorphine dose until stable drug effects are reached, with frequent monitoring for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is being stopped in someone on buprenorphine, an increase in the buprenorphine dose should be considered until stable drug effects are attained, along with monitoring for indications of opioid withdrawal2. When dose adjustment is not feasible once the CYP3A4 inhibitor is no longer present, the patient should be switched back to a buprenorphine formulation that allows for finer dose titration. For patients being transitioned from transmucosal buprenorphine given alongside CYP3A4 inhibitors, verify through monitoring that the plasma buprenorphine level achieved with subQ buprenorphine is sufficient. In those already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for signs and symptoms of over-medication. Should buprenorphine toxicity or overdose signs and symptoms develop while the concomitant drug cannot be lowered or stopped, decrease the buprenorphine dose. If the available doses are insufficient to reach the target dose, halt treatment and manage the patient using a buprenorphine formulation that supports more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring.
- Your team may reduce your buprenorphine dose while you are on lomitapide, and increase it again if lomitapide is stopped. Your dose may need to be individualized.
- They may monitor you more closely for sedation and slowed breathing, and for withdrawal symptoms if lomitapide is discontinued.
- If you use a long-acting or under-the-skin form, ask whether a formulation that allows more precise dose changes is a better fit.
Get help right away if you notice extreme drowsiness, confusion, or slow/shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, such interactions have been documented in studies employing transmucosal buprenorphine. The effects of buprenorphine may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Lomitapide together?
Lomitapide can raise buprenorphine levels and increase the risk of over-sedation and slowed breathing. Take both as prescribed, tell your care team you use both so they can adjust your dose and monitor you, and seek help for extreme drowsiness or slow breathing. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Lomitapide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Lomitapide interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring. Your team may reduce your buprenorphine dose while you are on lomitapide, and increase it again if lomitapide is stopped. Your dose may need to be individualized. They may monitor you more closely for sedation and slowed breathing, and for wi… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Lomitapide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Lomitapide
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist